200 research outputs found

    2020-05-08 DAILY UNM GLOBAL HEALTH COVID-19 BRIEFING

    Get PDF
    Executive Summary: UNM drug repurposing. NM cases. Doctors Without Borders. SNAP benefits online. NM 7th highest unemployment. Virtual LemonAid tonight. New N98 masks. Healthcare supply chain challenge. EMS lack resources. Infection risk in healthcare workers. COVID-19 on medical education. Human disinfectant chambers. Evidence of seroconversion. Dangers of considering herd immunity. Wastewater-based surveillance. More youths infected. Reconstructing ship spread. Pharmacoepidemiologic analysis. Clinicopathologic characteristics. Cancer treatment impact. Reduced voluntary psychiatric admission in Italy. Operating room management. Humidifiers reduce transmission. Phone contact tracing ethics. Call for patient database. Immunity certification program. Guidelines on tracheostomy, IBD, nose bleeding, pituitary tumors, and hematopoietic stem cells transplantation, benefits of low-PEEP, and of molecular diagnostics. FDA authorizes at-home test. Cephid Xpert test. MRSA nasal swabs. NIH remdesivir+barictinib RCT. Corticosteroid caution. Arbidol active in vitro. ACE/ARB systematic review. In silico phytochemical and virus protease candidates. Potential zinc benefit. 31 new clinical trials. Glycemic control benefit. Psychological effects meta-analysis and survey. Disease course model. Liver injury. Environmental and health perspectives. Olfactory and gustatory dysfunction. Vitamin D. Disease map

    2020-04-30 DAILY UNM GLOBAL HEALTH COVID-19 BRIEFING

    Get PDF
    Executive Summary: NM residential facility deaths. NM case update. NM TriCore testing antibodies. Navajo nation cases. May 10 Navajo peak. Udall funding push. El Paso shopping discouraged. NM budget shortfall. Santa Fe furlough. Ethanol sanitizer safety. LA free testing for all. Michigan protest. NM Batelle N95 decontamination. Hospital revenue decline. Wastewater early detection. German herd immunity. 60-day viral shedding possible. Temporary infected “ark”. Prison release preparedness. Low quality research. Phased long-term care. Suicide prevention. Corticosteroid tradeoffs. Cloth mask guidelines. SARS-CoV-2 assays compared. IgG and viral loads. Better testing reporting. Dubious testing vendors. Promising oral drug. Hydroxychloroquine prophylaxis dosing. Umifenovir ineffective. Multi-drug nanoparticles. Drug discovery new targets. 38 new COVID-19 trials. Cancer research review. Attenuated SARS-CoV-2

    2020-05-14 DAILY UNM GLOBAL HEALTH COVID-19 BRIEFING

    Get PDF
    Executive Summary: NM restrictions loosen. NM case count. Navajo Nation case count. 9 state parks open. Sunport revenue loss. Trump projects vaccine delivery. Wisconsin court case. Smokers quit. Ireland reopening. Danish schools open. Philippine typhoon evacuation. PPE-induced pressure injuries and facial dermatoses. U.S. mask stockpile. PPE for surgeons. Intubation time with aerosol box. Consumer spending with social restrictions. Suicide increase expected. Undetected virus homeless. Chinese infection control. 5% Spain infected. Sanitizing booth. Healthcare worker infection routes. Kawasaki disease France. CDC Kawaski guidance. Italian deaths characterized. CDC reopening school guidance. COVID-19 and epistemology. Monitoring misleading claims. UN mental health policy brief. CDC vaccination schedules. Guidelines on managing endoscopy units. COVID-19 lab testing (for lab professionals). Cancer surgery triage. Operating room practices. Orthodontic treatment. 3D printed NP swabs effective. Salt-water irrigation reduces duration. Corticosteroids ineffectual. Vaccines require biomanufacturing infrastructure. French pharm giant promises fair vaccine distribution. 26 new trials registered. LDH, lymphocytes and hs-CRP predict mortality. Fibrinogen higher in SARS. Insulin resistance. Glycemic monitoring. Hemostasis abnormalities. New phobia scale. OR global consensus. Inpatient cognitive assessments are challenging. Loud speech increases transmission. Monkeys present similarly. Human-to-dog transmission. Cat transmission

    The N-terminus of IpaB provides a potential anchor to the Shigella type III secretion system tip complex protein IpaD

    Get PDF
    The type III secretion system (T3SS) is an essential virulence factor for Shigella flexneri, providing a conduit through which host-altering effectors are injected directly into a host cell to promote uptake. The type III secretion apparatus (T3SA) is comprised of a basal body, external needle, and regulatory tip complex. The nascent needle is a polymer of MxiH capped by a pentamer of invasion plasmid antigen D (IpaD). Exposure to bile salts (e.g. deoxycholate) causes a conformational change in IpaD and promotes recruitment of IpaB to the needle tip. It has been proposed that IpaB senses contact with host cell membranes, recruiting IpaC and inducing full secretion of T3SS effectors. While the steps of T3SA maturation and their external triggers have been identified, details of specific protein interactions and mechanisms have remained difficult to study due to the hydrophobic nature of the IpaB and IpaC translocator proteins. Here we explored the ability for a series of soluble N-terminal IpaB peptides to interact with IpaD. We found that DOC is required for the interaction and that a region of IpaB between residues 11–27 is required for maximum binding, which was confirmed in vivo. Furthermore, intramolecular FRET measurements indicated that movement of the IpaD distal domain away from the protein core accompanied the binding of IpaB11-226. Together these new findings provide important new insight into the interactions and potential mechanisms that define the maturation of the Shigella T3SA needle tip complex and provide a foundation for further studies probing T3SS activation

    Does familial risk for alcohol use disorder predict alcohol hangover?

    Get PDF
    Positive family history of alcohol use disorder (FHP), a variable associated with propensity for alcohol use disorder (AUD), has been linked with elevated hangover frequency and severity, after controlling for alcohol use. This implies that hangover experiences may be related to AUD. However, inadequate control of alcohol consumption levels, low alcohol dose and testing for hangover during the intoxication phase detract from these findings. Here, we present further data pertinent to understanding the relationship between family history and alcohol hangover. Study 1 compared past year hangover frequency in a survey of 24 FHP and 118 family history negative (FHN) individuals. Study 2 applied a quasi-experimental naturalistic approach assessing concurrent hangover severity in 17 FHP and 32 FHN individuals the morning after drinking alcohol. Both studies applied statistical control for alcohol consumption levels. In Study 1, both FHP status and estimated blood alcohol concentration on the heaviest drinking evening of the past month predicted the frequency of hangover symptoms experienced over the previous 12 months. In Study 2, estimated blood alcohol concentration the previous evening predicted hangover severity but FHP status did not. FHP, indicating familial risk for AUD, was not associated with concurrent hangover severity but was associated with increased estimates of hangover frequency the previous year

    Influence of oral beclomethasone dipropionate on early non-infectious pulmonary outcomes after allogeneic hematopoietic cell transplantation: results from two randomized trials.

    Get PDF
    Early non-infectious pulmonary complications represent a significant cause of mortality after hematopoietic cell transplantation (HCT). We tested the hypothesis that oral beclomethasone dipropionate (BDP) is effective for preventing early non-infectious pulmonary complications after allogeneic HCT. We retrospectively reviewed the medical records of 120 patients, 60 in each treatment arm, to identify non-infectious and infectious pulmonary events and pulmonary function test results from all patients who participated in two randomized trials of oral BDP for treatment of acute gastrointestinal GVHD. 17-Beclomethasone monopropionate (17-BMP), the active metabolite of BDP, was evaluated in blood from the right atrium in four patients. Thirty-three of 42 (79%) placebo-treated patients experienced a decrease of the DL(CO) from pretransplant to day 80 after transplant, compared with 27 of 49 (55%) BDP-treated patients (P=0.02). In the first 200 days after randomization, there were no cases of non-infectious pulmonary complications in BDP-treated patients, vs four cases among placebo-treated patients (P=0.04). Levels of 17-BMP were detected in atrial blood at steady state. Delivery of a potent glucocorticoid such as 17-BMP to the pulmonary artery after oral dosing of BDP may be useful in modulating pulmonary inflammation and preventing the development of non-infectious pulmonary complications after allogeneic HCT.Bone Marrow Transplantation advance online publication, 29 June 2009; doi:10.1038/bmt.2009.129
    • 

    corecore